Merck & Co., Inc. stands tall in the pharmaceutical world, thanks to its rich portfolio of patented medicines, strong ties with healthcare providers, global reach, and decades of investment in drug research. The crown jewel of its strategy is the oncology powerhouse Keytruda, a cancer treatment that perfectly showcases Merck’s edge. Bringing a drug like Keytruda to market is not just about scientific discovery. It takes years of research, rigorous clinical trials, navigating regulatory hurdles, and building the infrastructure needed to deliver it worldwide. That is a level of commitment and complexity that most competitors cannot easily match.
But the pharmaceutical landscape is different from industries built on famous brands or recurring subscriptions. Patents eventually run out, new therapies come to market, and even blockbuster drugs can face tough price competition. For Merck, time is of the essence. Keytruda is expected to face biosimilar competitors by 2028 or 2029. The company has been working to expand its pipeline and make strategic deals, but drugs in development are not yet reliable sources of revenue. These challenges also make it worth comparing MRK with other income-generating companies, including those featured in Top 10 Unstoppable Dividend Stocks to Buy, before settling on a dividend strategy.
Also find MRK among 10 Best Bear Market Stocks to Invest In Right Now
Is the market’s optimism about Merck’s future already reflected in its forward P/E ratio?
Merck & Co., Inc. (NYSE:MRK) trades at a forward P/E ratio of 15.29, while its trailing P/E sits at a lofty 118.46. That gap is not just a quirk of the numbers. The company’s recent earnings have been unusually soft, making past multiples less helpful for judging the company’s real earning power. The forward P/E offers a clearer view, but it assumes that the company’s profits will rebound as analysts expect.
Merck’s valuation history shows why looking at a single low multiple can be misleading. In September 2025, its forward P/E was just 8.56. By June 2026, it had jumped to 25.38 before settling back to 15.29 more recently. These big moves do not mean the stock was mispriced. Instead, they highlight how Wall Street’s outlook on the pharmaceutical giant’s future earnings keeps changing.
At today’s prices, Merck’s forward P/E of 15.29 converts to an earnings yield of about 6.5%. For context, the 10-year US Treasury was yielding around 5.06% as of October 19, 2026. That means MRK shares offer a premium of only 1.5 percentage points over government bonds. It is a small cushion for taking on the risks of owning stocks, and it may not be enough if the company’s earnings fall when patents expire.
Merck’s lower valuation makes sense when you consider the bigger picture. While some of its peers have several fast-growing drugs, it relies a lot on Keytruda. That kind of focus, along with uncertainty about what will replace Keytruda in the future, makes investors cautious about paying a higher price. The real question for anyone looking at the company is not whether the P/E ratio is low, but whether the company’s pipeline can continue to support strong earnings. Read the full valuation analysis here: Merck’s Rally Reflects Renewed Confidence, but Has the Market Priced in Too Much?
Dividend Income: Not a Cure-All for Risk
Merck currently offers a forward dividend yield of about 2.4%, based on an annual payout of $3.40 per share. Investors receive $0.85 each quarter, which was increased by 4.9% in late 2025. For perspective, its five-year average yield is higher at 2.89%, so today’s income return is a little below what investors have seen in recent years. The company also holds a 16-year streak of growing its dividends. For a broader look at companies with established dividend records, have a look at the unstoppable dividend stocks list, which offers another starting point.
One number that may surprise some investors is Merck’s reported payout ratio of 266.67%. This means that it paid out much more in dividends than it earned on a GAAP basis last year, but this figure can be misleading. Sometimes, a year with weak earnings can make the ratio look worse than it really is. A better way to judge dividend safety is to look at free cash flow, which is the money left after all expenses and investments are covered.
Merck’s strong brand and steady cash flows are important supports for its dividend. The company’s consistent history of raising the dividend shows management’s commitment to shareholders. Still, investors should pay close attention to the upcoming expiration of Keytruda’s exclusivity. If the company’s new drugs do not bring in enough revenue to replace Keytruda, the company may have to slow down dividend increases in order to balance rewarding shareholders with investing in future innovation.
With a 2.4% yield, Merck is not a typical income stock. Its real appeal is the potential for dividend growth over time and possibly gains in the share price, rather than just a large initial payout. The dividend appears safe for now, given its ability to generate cash, but careful investors will keep an eye on free cash flow and pay attention to how quickly earnings recover, rather than relying only on Merck’s strong track record.
The Bottom Line
Merck has built a real competitive moat, but it will not last forever. Investors could see solid returns if the company’s pipeline produces as hoped. However, with only a modest premium over Treasury yields, there is little room for disappointment. The dividend is a welcome bonus, but what really matters for long-term returns is whether it can continue to generate strong, reliable earnings after Keytruda’s exclusivity comes to an end.
READ NEXT: Target (TGT) Has an Income Story. Does It Also Have a Growth Story? and ConocoPhillips’ 2.3% Yield Is Just the Start of the Story
This article is originally published at Insider Monkey.
Hedge Fund Resource Center